1C1m-Fc
CD-248
DOTA conjugation
Soft-tissue sarcoma
TEM-1
Theranostic
Journal
EJNMMI research
ISSN: 2191-219X
Titre abrégé: EJNMMI Res
Pays: Germany
ID NLM: 101560946
Informations de publication
Date de publication:
17 Aug 2020
17 Aug 2020
Historique:
received:
11
05
2020
accepted:
06
08
2020
entrez:
18
8
2020
pubmed:
18
8
2020
medline:
18
8
2020
Statut:
epublish
Résumé
TEM-1 (tumor endothelial marker-1) is a single-pass transmembrane cell surface glycoprotein expressed at high levels by tumor vasculature and malignant cells. We aimed to perform a preclinical investigation of a novel anti-TEM-1 scFv-Fc fusion antibody, 1C1m-Fc, which was radiolabeled with 1C1m-Fc was first conjugated to p-SCN-Bn-DOTA using different excess molar ratios and labeled with The DOTA conjugation and the labeling with TEM-1 is a promising target that could allow a theranostic approach to soft-tissue sarcoma, and 1C1m-Fc appears to be a suitable targeting candidate. In this study, we observed the influence of the ratio DOTA/antibody on the biodistribution. The next step will be to investigate the best conjugation to achieve an optimal tumor-to-organ radioactivity ratio and to perform therapy in murine xenograft models as a prelude to future translation in patients.
Identifiants
pubmed: 32804276
doi: 10.1186/s13550-020-00685-3
pii: 10.1186/s13550-020-00685-3
pmc: PMC7431510
doi:
Types de publication
Journal Article
Langues
eng
Pagination
98Références
Histopathology. 2014 Jan;64(1):2-11
pubmed: 24164390
Curr Med Chem. 2010;17(24):2636-55
pubmed: 20491631
Nucl Med Mol Imaging. 2018 Jun;52(3):208-215
pubmed: 29942399
Cancer Biol Ther. 2014 Apr;15(4):443-51
pubmed: 24553243
BMC Cancer. 2011 May 08;11:162
pubmed: 21549007
J Nucl Med. 2019 Aug;60(8):1174-1182
pubmed: 30733320
Nat Rev Immunol. 2011 Sep 23;11(10):702-11
pubmed: 21941296
Anticancer Agents Med Chem. 2018;18(1):146-153
pubmed: 28745238
Drug Discov Today. 2012 Nov;17(21-22):1224-32
pubmed: 22781499
Biomark Med. 2009 Oct;3(5):589-604
pubmed: 20477527
Nucl Med Biol. 2009 May;36(4):395-402
pubmed: 19423007
Cancer Med. 2015 Nov;4(11):1667-78
pubmed: 26336878
Clin Cancer Res. 2008 Nov 15;14(22):7223-36
pubmed: 19010839
FEBS Lett. 2007 Jul 24;581(18):3550-6
pubmed: 17628549
Mod Pathol. 2008 Mar;21(3):308-15
pubmed: 18192970
Proc Natl Acad Sci U S A. 2007 Nov 13;104(46):17965-70
pubmed: 17986615
Nucl Med Biol. 2006 Oct;33(7):883-9
pubmed: 17045168
ISRN Pharmacol. 2012;2012:417515
pubmed: 23227357
Sci Rep. 2019 Nov 27;9(1):17710
pubmed: 31776413
Oncotarget. 2019 Jan 29;10(9):993-1009
pubmed: 30847027
J Nucl Med. 2014 Mar;55(3):500-507
pubmed: 24525208
Clin Exp Metastasis. 2004;21(1):31-7
pubmed: 15065600
Sci Rep. 2019 Sep 6;9(1):12815
pubmed: 31492910
Mol Cancer Ther. 2015 Sep;14(9):2081-9
pubmed: 26184481
Eur J Cancer. 2018 Feb;90:111-121
pubmed: 29304474
Proc Natl Acad Sci U S A. 1992 Nov 15;89(22):10832-6
pubmed: 1438285
J Biol Chem. 2001 Oct 19;276(42):38795-807
pubmed: 11489895
BMC Med Genomics. 2011 Mar 28;4:26
pubmed: 21443790
J Immunother. 2003 Mar-Apr;26(2):139-48
pubmed: 12616105
FEBS Lett. 2005 May 9;579(12):2569-75
pubmed: 15862292
Proc Natl Acad Sci U S A. 2006 Feb 28;103(9):3351-6
pubmed: 16492758
Cancer Immunol Immunother. 2018 Feb;67(2):329-339
pubmed: 29313073
Oncotarget. 2017 Jul 22;8(36):60368-60377
pubmed: 28947977
Ann Surg Oncol. 2010 Jun;17(6):1471-4
pubmed: 20180029
J Immunol Methods. 1984 Aug 3;72(1):77-89
pubmed: 6086763
Br J Cancer. 2016 Aug 9;115(4):473-9
pubmed: 27434038
Nucl Med Biol. 2011 Nov;38(8):1119-27
pubmed: 21741258
J Biol Chem. 2001 Dec 21;276(51):48588-95
pubmed: 11559704
Protein Eng Des Sel. 2014 Oct;27(10):317-24
pubmed: 25095796
Bioconjug Chem. 2016 Oct 19;27(10):2460-2468
pubmed: 27617674